DESAIN VAKSIN HUMAN PAPILLOMAVIRUS TIPE 16 BERDASARKAN HUMAN LEUKOCYTE ANTIGEN POPULASI INDONESIA MELALUI PENDEKATAN REVERSE VACCINOLOGY

• Main Author: Puteri Mariyani, Dina
• Format: Final Project
• Language: Indonesia
• Online Access: https://digilib.itb.ac.id/gdl/view/57963
• Institution: Institut Teknologi Bandung

Cervical cancer is the second most common cancer case after breast cancer in Indonesia. About 50-60% of cancer cases are triggered by High Risk Human Papillomavirus (HR-HPV), HPV-16. Although vaccine can protect 70%-90% against the HR-HPV strain, the vaccine is not therapeutic virally infected people. This research aim to design a multi-epitope vaccine, for the Indonesian population, which has both a therapeutic and prophylactic effect against HPV-16 from a combination of E6, E7, and L1 proteins using a Reverse Vaccinlogy Indonesian Human Leukocyte Antigen (HLA). 757 E7 sequences, 403 L1 sequences, and 2773 E6 sequences in NCBI determined each conserved region and analyzed the epitope using a web server. As a result, we selected eight CD8+ T cell epitopes, four CD4+ T cell epitopes and three B cell epitopes of E7 and L1 protein epitopes. Then the epitope linked with the adjuvant 50S ribosomal protein L7/L12 (rplL) from Mycobacterium tuberculosis, PADRE sequence, and linker. Finally, we analyzed the allergenicity antigenicity, physicochemical, 3D structure, and molecular docking parameters. In addition, we found the vaccine candidate with a 99.99% population coverage of Indonesian and predicted to have stable, hydrophilic, antigenic, thermostable. The theoretical pI was 4.67, non-allergenic, and has a halflife of about 1 hour in the human body. The ERRAT score is 91.56, the Z-score value of -7.87, and the Ramachandra plot value of 96.3% shows a good result. Furthermore, the interaction between vaccine candidate and Toll-Like Receptor (TLR) 4 may occur, indicated by a negative G value and the presence of critical residues. In summary, the vaccine candidate hopefully can induce a cellular immune response in the body in the pre-clinical trial.